New Delhi, April 13 -- The Indian pharmaceutical industry aims for a strategic transition from its traditional role as a volume-driven generics producer toward becoming a value-led innovation hub focused on biologics and biosimilars. This shift comes as the government implements significant financial and regulatory reforms to align the sector with evolving global health requirements and technological advancements.

Speaking to the media at the sidelines of the 9th edition of 'India Pharma 2026', Union Minister of State for Chemicals & Fertilizers and Health & Family Welfare Anupriya Patel highlighted the critical nature of this industrial evolution. She noted that the Department of Pharmaceuticals is actively working to expand the domesti...